lartexa 20 mg/1 tableta filmom obložena tableta
amsal pharmaceuticals d.o.o. - leflunomide - filmom obložena tableta - 20 mg/1 tableta - 1 filmom obložena tableta sadrži: 20 mg leflunomida
arava 20mg film tableta
amicus pharma doo podgorica - leflunomid - film tableta - 20mg
aubagio
sanofi winthrop industrie - teriflunomide - multipla skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
revolade 25 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - eltrombopag - filmom obložena tableta - 25 mg/1 tableta - 1 filmom obložena tableta sadrži: 25 mg eltrombopag (u obliku eltrombopag olamina)
revolade 50 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - eltrombopag - filmom obložena tableta - 50 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg eltrombopag (u obliku eltrombopag olamina)
aubagio 14 mg/1 tableta film tableta
sanofi d.o.o. - teriflunomid - film tableta - 14 mg/1 tableta - 1 film tableta sadrži: 14 mg teriflunomida
aubagio 14 mg/1 tableta film tableta
amicus pharma d.o.o. - teriflunomid - film tableta - 14 mg/1 tableta - 1 film tableta sadrži: 14 mg teriflunomida
revolade 25 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - eltrombopag - filmom obložena tableta - 25 mg/1 tableta - 1 filmom obložena tableta sadrži: 25 mg eltrombopag (u obliku eltrombopag olamina)
revolade 50 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - eltrombopag - filmom obložena tableta - 50 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg eltrombopag (u obliku eltrombopag olamina)
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).